

# Thomas Aagaard Rasmussen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/169376/thomas-aagaard-rasmussen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

2,322  
citations

21  
h-index

47  
g-index

60  
ext. papers

2,810  
ext. citations

6.5  
avg, IF

4.82  
L-index

#	Paper	IF	Citations
54	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabl3836	17.5	6
53	Immune checkpoint blockade in HIV.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103840	8.8	1
52	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , <b>2022</b> , 36, 75-825	8.5	2
51	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , <b>2021</b> , 65, 103241	8.8	11
50	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , <b>2021</b> , 65, 103252	8.8	5
49	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1973-e1981	11.6	11
48	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , <b>2021</b> , 35, 1631-1636	3.5	2
47	Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound. <i>Aids</i> , <b>2021</b> , 35, 2269-2279	3.5	2
46	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , <b>2021</b> ,	5.3	2
45	Kick and kill for HIV latency. <i>Lancet, The</i> , <b>2020</b> , 395, 844-846	40	6
44	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , <b>2020</b> , 33, 108502	10.6	10
43	Between a shock and a hard place: challenges and developments in HIV latency reversal. <i>Current Opinion in Virology</i> , <b>2019</b> , 38, 1-9	7.5	31
42	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 133-137	2.8	8
41	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , <b>2019</b> , 33, 605-613	3.5	13
40	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , <b>2018</b> , 3,	5	11
39	Patient-reported outcomes in daily clinical practise in HIV outpatient care. <i>International Journal of Infectious Diseases</i> , <b>2018</b> , 69, 108-114	10.5	14
38	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e221-e230	7.8	19

37	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , <b>2018</b> , 1075, 285-318	3.6	13
36	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	7
35	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	15
34	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , <b>2017</b> , 31, 1137-1141	3.5	9
33	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 328-337	3.1	21
32	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , <b>2017</b> , 12, 96-104	4.2	16
31	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , <b>2017</b> , 31, 1839-1845	3.5	6
30	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	11
29	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1686-1695	11.6	82
28	Modeling of Antilateny Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	9
27	Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. <i>Aids</i> , <b>2017</b> , 31, 771-779	3.5	23
26	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	45
25	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , <b>2016</b> , 7, 12731	17.4	56
24	Reversal of Latency as Part of a Cure for HIV-1. <i>Trends in Microbiology</i> , <b>2016</b> , 24, 90-97	12.4	73
23	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e8-10	7.8	17
22	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells. <i>Journal of Virology</i> , <b>2016</b> , 90, 4441-4453	6.6	64
21	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005740	7.6	16
20	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. <i>Aids</i> , <b>2016</b> , 30, 713-21	3.5	14

19	Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?. <i>Current Opinion in HIV and AIDS</i> , <b>2016</b> , 11, 394-401	4.2	98
18	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e463-72	7.8	126
17	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. <i>Journal of Virology</i> , <b>2015</b> , 89, 10176-89	6.6	63
16	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. <i>Aids</i> , <b>2015</b> , 29, 1195-200	3.5	17
15	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005000	7.6	73
14	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005142	7.6	352
13	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 120605	4.3	7
12	Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. <i>Molecular Medicine</i> , <b>2015</b> , 21, 337-45	6.2	30
11	Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3984-94	5.9	18
10	Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv037	1	35
9	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV,the</i> , <b>2014</b> , 1, e13-21	7.8	421
8	Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , <b>2013</b> , 9, 790-9	4.4	40
7	Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. <i>Human Vaccines and Immunotherapeutics</i> , <b>2013</b> , 9, 993-1001	4.4	149
6	Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e62074	3.7	39
5	Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. <i>BMJ, The</i> , <b>2012</b> , 345, e5823	5.9	18
4	Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. <i>PLoS ONE</i> , <b>2012</b> , 7, e32445	3.7	49
3	Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. <i>Molecular Medicine</i> , <b>2011</b> , 17, 466-72	6.2	77
2	Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 267	4	20

- 1 Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. *Aids*, **2010**, 24, 1315-22 3.5 23